Special Issue

Assessment of Avian Influenza Vaccine: Biochemical Characterization and Genetic Identification of Virus Strains

Message from the Guest Editors

At present, vaccination was believed to be the most effective way on prevention and control of influenza. However, a major difficulty in the development of pre-pandemic vaccines is to identify which zoonotic virus may cause the next pandemic. To promote the technological preparedness or theoretical recognition on potential influence pandemic, we are launching a Special Issue entitled "Assessment of Avian Influenza Vaccine: Biological Characterization and Genetic Identification of Virus Strains". This Special Issue will include high-quality papers on topics within the broad scope of *Vaccines*. We will consider manuscripts that investigate anti-viral and anti-influenza immunity, immunological responses to potential viral vaccine antigens, the testing of viral vaccine candidates in animals and humans, the delivery methods of viral vaccine antigens, studies on vaccine adjuvants related to viral vaccine development, investigations of viral vaccine strategies that aim to raise broadly neutralizing antibodies, and theoretical studies that suggest and rationalize novel types of viral vaccines or novel ways of stimulating protective anti-viral immunity.

Guest Editors

Dr. Rongbao Gao

Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Dr. Li Xin

WHO Collaborating Center for Reference and Research on Influenza, Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

Deadline for manuscript submissions

closed (31 October 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/158265

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).